VYNE Therapeutics Q3 net loss narrows, strategic review ongoing
VYNE Therapeutics reported a narrowed Q3 net loss of $7.28 million, with revenue of $169,000. The company is undergoing a strategic review to explore partnerships or mergers, aiming to maximize shareholder value. Cost reductions have been implemented to extend the cash runway into the first half of 2027. Analysts maintain a "buy" rating on the stock, with a median 12-month price target of $3.25, significantly above its recent closing price of $0.34.
)
Overview
- VYNE Q3 net loss decreases compared to last year
- Company progressing with strategic review to maximize shareholder value
Outlook
- VYNE is conducting a strategic review to explore options like partnerships or mergers
- Company expects cash runway to last into the first half of 2027
- VYNE is conducting a 12-week toxicology study for VYN202 to lift a clinical hold
Result Drivers
- STRATEGIC REVIEW - Co is evaluating strategic alternatives to maximize shareholder value, including potential partnerships and transactions
- COST REDUCTIONS - Co implemented cost reductions to extend cash runway into first half of 2027
Key Details
Metric Beat/Mis Actual Consensu
s s
Estimate
Q3 $169,000
Revenue
Q3 Net -$7.28
Income mln
Q3 EPS -$0.17
from
Cont Ops
Analyst Coverage
- The current average analyst rating on the shares is “buy” and the breakdown of recommendations is 2 “strong buy” or “buy”, 2 “hold” and no “sell” or “strong sell”
- The average consensus recommendation for the biotechnology & medical research peer group is “buy”
- Wall Street’s median 12-month price target for Vyne Therapeutics Inc is $3.25, about 89.6% above its November 5 closing price of $0.34
Press Release: For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact . (This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)
